TCIM
NERV icon

TIAA CREF Investment Management’s Minerva Neurosciences NERV Stock Holding History

TIAA CREF Investment Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.88M Buy
29,937
+1,124
+4% +$67.6K ﹤0.01% 2030
2018
Q4 		$1.55M Buy
28,813
+2,664
+10% +$195K ﹤0.01% 2098
2018
Q3 		$2.63M Buy
26,149
+4,965
+23% +$373K ﹤0.01% 1979
2018
Q2 		$1.4M Buy
21,184
+1,942
+10% +$118K ﹤0.01% 2352
2018
Q1 		$962K Buy
19,242
+841
+5% +$40.4K ﹤0.01% 2460
2017
Q4 		$891K Buy
18,401
+301
+2% +$14.9K ﹤0.01% 2519
2017
Q3 		$1.1M Buy
18,100
+7,569
+72% +$434K ﹤0.01% 2472
2017
Q2 		$746K Buy
10,531
+4,322
+70% +$280K ﹤0.01% 2688
2017
Q1 		$402K Sell
6,209
-225
-3% -$17.5K ﹤0.01% 2869
2016
Q4 		$605K Sell
6,434
-568
-8% -$58K ﹤0.01% 2773
2016
Q3 		$791 Buy
7,002
+474
+7% +$46K ﹤0.01% 2650
2016
Q2 		$533K Buy
+6,528
New +$415K ﹤0.01% 2828

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return

TIAA CREF Investment Management's NERV Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Minerva Neurosciences (NERV) stake by 3.9% in Q1 2019, buying an estimated $67.6K and bringing the position to 29,937 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

TIAA CREF Investment Management first reported a position in NERV in Q2 2016 and has held it in 12 quarters since. The position peaked at $2.63M in Q3 2018. 79 funds tracked by Wall St. Rank hold NERV as of Q1 2019.

  • TIAA CREF Investment Management held 29,937 shares of Minerva Neurosciences worth $1.88M as of Q1 2019.
  • TIAA CREF Investment Management bought 1,124 Minerva Neurosciences shares in Q1 2019, an estimated $67.6K.
  • Minerva Neurosciences made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2030 holding.
  • TIAA CREF Investment Management first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 12 quarters since.
  • TIAA CREF Investment Management's Minerva Neurosciences position peaked at $2.63M in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.